Arvinas, Inc. (ARVN): Revenue
$262.60M
Year ended 2025-12-31
$316.70M
Trailing 12 months to 2026-06-30
+26.0%
3-year compound annual growth
+58.9%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $262.60M | -0.3% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $263.40M | +235.5% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $78.50M | -40.3% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $131.40M | +145.1% | 2025-02-11, From 2022-01-01 |
| 2021-12-31 | $53.60M | +106.9% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $25.90M | n/c | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $43.00M | +200.2% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $14.32M | +89.0% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $7.58M | n/a | 2019-03-26, From 2017-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Arvinas, Inc. (ARVN) | 2025-12-31 | $262.60M | -0.3% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $268.09M | +60.4% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $268.77M | +170.4% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $255.87M | +23.3% |
| Harrow, Inc. (HROW) | 2025-12-31 | $272.30M | +36.4% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $247.00M | -4.3% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $244.06M | n/m |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $291.85M | +43.7% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $236.20M | +47.5% |
Compare ARVN, LGND, VREOF, SDGR side by side · Screen every company in Pharmaceutical Preparations ↗